Pharmacokinetics, Pharmacodynamics, and Safety of the Highly Selective Dopamine D1/D5 Agonist Tavapadon: Summary of Phase 1 Clinical Studies (P10-11.001)

Tuesday, April 5May 3, 2022Free AccessPharmacokinetics, Pharmacodynamics, and Safety of the Highly Selective Dopamine D1/D5 Agonist Tavapadon: Summary of Phase 1 Clinical Studies (P10-11.001)Gina Pastino, Josh Yuan, Sridhar Duvvuri, Matthew Leoni, Kimberly Largay, Ih Chang, Amy Giugliano, Stacey Versavel, David Gray, Raymond Sanchez, and John RengerAuthors Info & AffiliationsMay 3, 2022 issue98 (18_supplement)https://doi.org/10.1212/WNL.98.18_supplement.2728 Letters to the Editor